Navigation Links
Fuld & Company Announces Appointment of MIT Fellow to Head Pharmaceutical Team's Strategic Gaming and Consulting Services
Date:12/16/2008

CAMBRIDGE, Mass., Dec. 16 /PRNewswire/ -- Fuld & Company today announced that Wayne Rosenkrans, Ph.D., will join the Company as vice president consulting, specializing in strategic gaming for the pharmaceutical and healthcare industries.

"We are excited to have Dr. Rosenkrans join the Fuld team," said Leonard Fuld, president. "His extensive accomplishment in the global pharmaceutical industry; government and academia -- coupled with his involvement on the cutting edge of personalized medicine -- makes him an extraordinary asset for our clients."

Fuld & Company's Pharmaceuticals Practice provides all levels of competitive support from research to consulting. The firm has serviced over 100 biotech, pharmaceutical and diagnostics/device companies for training, custom research, and systems consulting needs. Fuld assesses new product progress from early-stage development to product launch, technology partnerships between biotech and big pharma, as well as changing global technologies, regulations, and markets. The firm has researched over 60 different therapeutic categories worldwide.

Rosenkrans is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare strategy and policy issues related to science and medicine. He is also Chairman, President and a member of the board of directors of the Personalized Medicine Coalition, a Washington DC-based organization working with government and other agencies on evolving healthcare policy for Personalized Healthcare. He is also Chief Applications Officer for SciTech Strategies, focusing on scientific competency and capacity development for academia and industry.

Previously, Rosenkrans served as Director of External Relations for the Personalized Healthcare Team and Evidence-based Medicine (EBM) at AstraZeneca where he had responsibility for long-range external relations strategy and policy development. He has presented at numerous forums on aspects of personalized healthcare, evidence-based medicine, new development paradigms, and strategy development.

Rosenkrans holds an S.B. in Biology from MIT, a Ph.D. in Cell and Molecular Biology from Boston University, and received post-doctoral training in Cancer and Radiation Biology at the University of Rochester.

Fuld & Company, based in Cambridge, Mass., with offices in London, is the world's preeminent research and consulting firm in the field of competitive intelligence. Founded by Leonard Fuld, a pioneer and recognized leading authority in the field, Fuld & Company is a full-service competitive intelligence firm, providing research and analysis, strategic gaming, intelligence process consulting, and training to help clients understand the external competitive environment. The firm's mission is to help clients improve their performance by making better decisions through the application of solid intelligence on their markets and competitors. Additional information can be found at: www.fuld.com.


'/>"/>
SOURCE Fuld & Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
2. Myngle Best ICT Company at the European Ventures Summit
3. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
4. ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
5. CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market
6. The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
7. CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market
8. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
9. Michigan Company Founded upon What Could Be History's Most Important Breakthrough in AI and Robotics
10. Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloittes 2008 Technology Fast 500
11. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... Rob Lowe ... public television series. This series, called "Informed," focuses on issues that are important to ... on the climate change issue, which has been a hot topic around the world ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... the deadline to participate in its previously announced ... consisting of shares of common stock and Series ... holders of listed warrants. As ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... FireflySci, Inc ... Founded in late 2014, FireflySci had the goal of bringing their powerful cuvette ... continues to shape the path that FireflySci is going on as they add yet ...
(Date:2/23/2017)... SAN RAFAEL, Calif., Feb. 23, 2017 ... of U.S. dollars, except per share data, unaudited)Three Months ... ChangeTotal BioMarin Revenue $ ...     22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
(Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
Breaking Biology News(10 mins):